NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
12634-0188-84 | 12634-0188 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 26, 1974 | In Use | |
63323-0140-10 | 63323-0140 | Cladribine | Cladribine | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Dec 1, 2004 | In Use | |
00338-9779-01 | 00338-9779 | Cyclophosphamide injection, solution | Cyclophosphamide | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Aug 1, 2024 | In Use | |
63629-4413-03 | 63629-4413 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Mar 7, 2011 | In Use | ||
67184-0501-01 | 67184-0501 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 11, 2016 | In Use | |
00310-9500-02 | 00310-9500 | Capivasertib | TRUQAP | 160.0 mg/1 | Chemotherapy | AKT Inhibitor | AKT1/2/3 | Oral | Oct 18, 2024 | In Use | |
00310-9501-95 | 00310-9501 | Capivasertib | TRUQAP | 200.0 mg/1 | Chemotherapy | AKT Inhibitor | AKT1/2/3 | Oral | Feb 1, 2024 | Oct 28, 2024 | In Use |
00378-6612-93 | 00378-6612 | Isotretinoin | Amnesteem | 20.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov 11, 2002 | In Use | |
00378-6614-88 | 00378-6614 | Isotretinoin | Amnesteem | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov 11, 2002 | Jul 24, 2013 | In Use |
00409-0801-01 | 00409-0801 | Pentostatin | Nipent | 2.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug 15, 2007 | In Use | |
00409-0201-10 | 00409-0201 | DOCETAXEL ANHYDROUS | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 17, 2011 | In Use | |
00409-3414-11 | 00409-3414 | Metoclopramide | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Aug 26, 2024 | In Use | |
00469-1425-90 | 00469-1425 | Gilteritinib | Xospata | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | Nov 29, 2018 | In Use | |
40051-0607-12 | 40051-0607 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
00069-4031-01 | 00069-4031 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Mar 5, 2013 | Apr 30, 2021 | In Use |
55513-0005-04 | 55513-0005 | Darbepoetin alfa | Aranesp | 100.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
16571-0818-02 | 16571-0818 | Temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 4, 2022 | In Use | |
68001-0527-54 | 68001-0527 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Feb 15, 2022 | In Use | |
00703-3675-91 | 00703-3675 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous | Jan 30, 2013 | Feb 28, 2017 | In Use |
42023-0110-01 | 42023-0110 | Estradiol Valerate | Delestrogen | 10.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | Nov 1, 2007 | In Use | ||
55513-0006-01 | 55513-0006 | Darbepoetin alfa | Aranesp | 200.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
00480-4515-01 | 00480-4515 | Pemetrexed | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 31, 2022 | In Use | |
55513-0021-01 | 55513-0021 | Darbepoetin alfa | Aranesp | 40.0 ug/.4mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Feb 18, 2011 | In Use | ||
55513-0021-04 | 55513-0021 | Darbepoetin alfa | Aranesp | 40.0 ug/.4mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 14, 2006 | In Use | ||
55150-0395-08 | 55150-0395 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Jun 25, 2024 | In Use |
Found 11120 results — Export these results